|
|
Article: RenaGel Reduces Morbidity, Lowers Costs in Dialysis Patients.
- Article from:
- Family Practice News
- Article date:
- July 1, 2000
- Author:
CopyrightCOPYRIGHT 2000 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ATLANTA -- The use of the calcium- and aluminum-free phosphate binder sevelamer to control hyperphosphatemia in dialysis patients results in a sharply reduced hospitalization rate and an impressive reduction in health care costs, Dr. Allan J. Collins reported at a meeting on clinical nephrology sponsored by the National Kidney Foundation.
Indeed, the estimated savings in Medicare Parts A and B expenditures attained through the use of sevelamer (RenaGel) in his case-control study amounted to $17,328 per treated patient per year, compared with conventional management, according to Dr. Collins, professor of medicine at the University of Minnesota in Minneapolis and ...